ClinicalTrials.gov
public full text
Public Domain
PRecision Oncology Evidence Development in Cancer Treatment - Liquid
The current standard of care for molecular characterization of tumors is tissue based next generation sequencing (NGS) panel. Liquid biopsies (ie blood) are of increasing interest and have been implemented as a diagnostic tool in some countries. This study compares tissue based and liquid based testing to evaluate the detection rate and cost consequence of using this new tool in BC.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A liquid biopsy-centered, pan-cancer, open next generation sequencing panel to support clinical decision-making (LION panel)#343641
- Physician- and Patient-based Barriers to NGS Testing#860979
- The Added Value of Tissue or Liquid Biopsy NGS Profiling in Advanced Solid Tumor Treatment Decisions.#883596
- Carcinoma of Unknown Primary (CUP): a Comparison Across Tissue and Liquid Biomarkers#901095
- Epitranscriptomic liquid biopsy: A new paradigm for early detection and management of gastrointestinal cancers#1390532
Record · ID 1454552
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive